Skip to main content
Figure 8 | BMC Cancer

Figure 8

From: MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer

Figure 8

Effects of MP470-Erlotinib combination on Akt phosphorylation in xenograft tissues. IHC analysis for Akt activity was performed on the tumors harvested at the end of the treatment of an LNCaP xenograft mouse model. Paraffin embedded sections were immuno-stained for expression of phosphorylated Akt (Ser473). Tumors from mice treated with the MP470-Erlotinib combination had a near complete inhibition of Akt phosphorylation compared to control or individual therapies (200 ×).

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us